These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 20920857)

  • 1. [Consensus document on the use of granulocyte colony stimulating factor biosimilars for correction of neutropenia in cancer patients].
    Aranda Aguilar E; Camps Herrero C; Carrato Mena A; Clopés Estela A; Cruz Hernández JJ; Delgado Sánchez O; Díaz-Rubio García E; Domínguez-Gil Hurlé A; Dorantes Calderón B; García Alfonso P; Herrero Ambrosio A
    Farm Hosp; 2010 Mar; 34 Suppl 1():45-50. PubMed ID: 20920857
    [No Abstract]   [Full Text] [Related]  

  • 2. Prevention and treatment of chemotherapy-induced neutropenia with the biosimilar filgrastim: a non-interventional observational study of clinical practice patterns.
    Tesch H; Ulshöfer T; Vehling-Kaiser U; Ottillinger B; Bulenda D; Turner M
    Oncol Res Treat; 2015; 38(4):146-52. PubMed ID: 25877937
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Biosimilar filgrastim: from development to record].
    García Alfonso P
    Farm Hosp; 2010 Mar; 34 Suppl 1():19-24. PubMed ID: 20920854
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Biosimilar medicines in oncology: single-center experience with biosimilar G-CSF.
    Salesi N; Di Cocco B; Colonna M; Veltri E
    Future Oncol; 2012 May; 8(5):625-30. PubMed ID: 22401144
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Granulocyte colony-stimulating factors in the management of chemotherapy-induced neutropenia: evidence based review.
    Bhana N
    Curr Opin Oncol; 2007 Jul; 19(4):328-35. PubMed ID: 17545795
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Antineoplastic drug-induced neutropenia: use of granulocyte colony stimulating factors].
    Carrato A; Guillén-Ponce C; Grande-Pulido E
    Farm Hosp; 2010 Mar; 34 Suppl 1():8-11. PubMed ID: 20920851
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Tips on the use of granulocyte colony-stimulating factors in cancer patients predisposed to chemotherapy - induced febrile neutropenia].
    Murakawa Y
    Gan To Kagaku Ryoho; 2013 Jun; 40(6):693-6. PubMed ID: 23863645
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Optimal use of recombinant granulocyte colony-stimulating factor with chemotherapy for solid tumors.
    Danova M; Barni S; Del Mastro L; Danesi R; Pappagallo GL
    Expert Rev Anticancer Ther; 2011 Aug; 11(8):1303-13. PubMed ID: 21916584
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of a formulary change from granulocyte colony-stimulating factor to granulocyte-macrophage colony-stimulating factor on outcomes in patients treated with myelosuppressive chemotherapy.
    Wong SF; Chan HO
    Pharmacotherapy; 2005 Mar; 25(3):372-8. PubMed ID: 15843284
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Optimal use of granulocyte-colony-stimulating factor in patients with cancer who are at risk for chemotherapy-induced neutropenia.
    Cappozzo C
    Oncol Nurs Forum; 2004 May; 31(3):569-76. PubMed ID: 15146222
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Emerging agents for the prevention of treatment induced neutropenia in adult cancer patients.
    Matikas A; Georgoulias V; Kotsakis A
    Expert Opin Emerg Drugs; 2016 Jun; 21(2):157-66. PubMed ID: 27139914
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Febrile neutropenia: highlighting the role of prophylactic antibiotics and granulocyte colony-stimulating factor during standard dose chemotherapy for solid tumors.
    Timmer-Bonte JN; Tjan-Heijnen VC
    Anticancer Drugs; 2006 Sep; 17(8):881-9. PubMed ID: 16940798
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Place of CSF in pediatric oncology].
    Hartmann O; Valteau-Couanet D
    Pathol Biol (Paris); 1993 Jan; 41(1):52. PubMed ID: 7686289
    [No Abstract]   [Full Text] [Related]  

  • 14. [Rational therapy with hematopoetic growth factors (G-CSF, GM-CSF) for patients in neutropenia].
    Kahl C; Leithäuser M; Freund M
    Dtsch Med Wochenschr; 2002 Jul; 127(27):1473-8. PubMed ID: 12098099
    [No Abstract]   [Full Text] [Related]  

  • 15. Service plans and clinical interventions targeted by the oncology pharmacist.
    Pon D
    Pharm Pract Manag Q; 1996 Apr; 16(1):18-30. PubMed ID: 10157737
    [TBL] [Abstract][Full Text] [Related]  

  • 16. NCCN guidelines advocate wider use of colony-stimulating factor.
    McNeil C
    J Natl Cancer Inst; 2005 May; 97(10):710-1. PubMed ID: 15900037
    [No Abstract]   [Full Text] [Related]  

  • 17. Introduction and commentary: Paving the way for biosimilars in oncology.
    Abraham J
    Semin Oncol; 2013 Dec; 40 Suppl 1():S1-4. PubMed ID: 24267943
    [No Abstract]   [Full Text] [Related]  

  • 18. [Therapeutic intensification: contribution of G-CSF].
    Marty M; Extra JM; Giacchetti S
    Pathol Biol (Paris); 1993 Jan; 41(1):53-5. PubMed ID: 7686290
    [No Abstract]   [Full Text] [Related]  

  • 19. Introduction and commentary: paving the way for biosimilars in oncology, part 2: focus on safety and clinical trial considerations.
    Abraham J
    Semin Oncol; 2014 Feb; 41 Suppl 1():S1-2. PubMed ID: 24560023
    [No Abstract]   [Full Text] [Related]  

  • 20. The role of biosimilar granulocyte colony stimulating factor (GCSF) Zarzio for progenitor cell mobilization and the treatment of therapy-induced neutropenia in adult hematopoietic stem cell transplantation.
    Severson CC
    Can Oncol Nurs J; 2015; 25(4):443-54. PubMed ID: 26897866
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.